免疫检查点抑制剂的抗肿瘤临床实践与展望  

Immune checkpoint inhibitors in anti-cancer therapy:practice and perspective

作　　者：陈若雪 杜晓静 安泉林 曹鑫 CHEN Ruo-xue;DU Xiao-jing;AN Quan-lin;CAO Xin(Biomedical Research Center, Zhongshan Hospital, Fudan University, Shanghai 200032, China;Department of Gastroenterology, Minhang Hospital, Fudan University, Shanghai 201199, China)

机构地区：[1]复旦大学附属中山医院实验研究中心,上海200032 [2]复旦大学附属闵行医院消化内科,上海201199

出　　处：《中国临床医学》2021年第1期3-8,共6页Chinese Journal of Clinical Medicine

基　　金：上海市科学技术委员会面上项目(20ZR1410400);复旦大学“卓越2025”卓学优秀人才计划,浙江省胰腺肝脏危重性疾病诊治新技术研究重点实验室开放基金.

摘　　要：基于靶向免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)的肿瘤免疫治疗在近10年取得了重要进展,程序性死亡因子-1(PD-1)/程序性死亡因子配体-1(PD-L1)抗体治疗则成为肿瘤治疗领域最具潜力的新型疗法。中国肿瘤学者与发达国家学者基本同步开展的肿瘤免疫疗法的临床实践,进一步验证了肿瘤免疫治疗的效果。伴随临床应用数据的积累,ICIs抗肿瘤疗法逐渐暴露出很多不足,如总体治疗应答率偏低、获得性耐药机制复杂以及免疫相关不良反应(irAEs)多有发生等。这些问题都值得引起相关领域专家重视。本文总结了近年来国内外ICIs的临床实践成果,深入分析了当前ICIs疗法面临的挑战,探讨并提出了改善患者获益的策略。Cancer immunotherapy based on immune checkpoint inhibitors(ICIs)represents the promising advances over the past decade.Demonstrating unprecedented extension of patient survival,antibodies against programmed cell death 1(PD-1)and its ligand(PD-L1)quickly became the promising novel treatment in anti-cancer therapeutics nowadays.So,immunotherapy of cancer has entered into a new phase.Clinical trials and practices conducted simultaneously by oncologists both in China and the developed countries furtherly proved the clinical efficiency of agents targeting ICIs in treatment of a wide array of cancer types.However,despite the success of ICIs,side effects of antibody targeting ICIs gradually emerged during the widespread use in clinic,including the low overall response rates(ORRs),acquired resistance to these agents,and various immune-related adverse events(irAEs),of which are worthy of attention of the oncologists.This paper summarized the recent progress of ICIs in clinics,discussed the above challenges,and proposed the strategy for increasing benefits of the ICIs therapy.

关 键 词：肿瘤 免疫检查点抑制剂 PD-1/PD-L1抗体 获得性药物耐药 免疫相关不良反应 

分 类 号：R979.5[医药卫生—药品]